By Tasos Zachos · Fortune Greece · 18/11/2026
Eleni Pentafragka, a representative of the third generation of the family-owned pharmaceutical company and CEO of the new Park, talks about the country’s untapped scientific potential, opportunities in clinical research, and the ambition to strengthen Greece’s contribution to discovering and developing new treatments by drawing on its manufacturing and research base.
For Eleni Pentafragka, the challenge ahead for the Greek pharmaceutical industry is not limited to manufacturing and exporting medicines. It also involves moving into original innovation: giving Greece the ability to make a meaningful contribution to discovering and developing new treatments. As Chief Strategy Officer and a member of ELPEN’s Board of Directors, she represents the third generation of a family business that has consistently invested in domestic production, research and international expansion.
Today, she hopes to contribute to the next chapter of this journey. That ambition is taking concrete shape through Athens LifeTech Park, where she is CEO and a member of the Board.
The Park is an €80 million strategic investment by ELPEN in Spata, part of a broader investment programme of €380 million through 2030. The first biotechnology park in Southeastern Europe aims to address a longstanding gap: the absence of an organised environment connecting scientific research with specialist infrastructure, investment capital and business development.
Behind the investment is a consistent business culture. For more than six decades, ELPEN has chosen to maintain and develop its manufacturing and research base in Greece. According to the company, it reinvests more than 15% of its annual turnover in research and development. Athens LifeTech Park is the next ambitious step: creating infrastructure that will serve not only the company itself, but also support a broader, internationally connected biotechnology ecosystem.
In this interview, Pentafragka explains why scientific talent alone is not enough to create a competitive biotechnology industry. She highlights clinical trials as an important opportunity for Greece and describes how the country could attract international research teams and investment. Above all, she talks about the personal and business challenge facing her generation: helping new treatments reach patients after part of their journey has taken place in Greece.
The interview took place as part of the Power of Innovation Summit 2026.
Greece has outstanding scientists in the health and life sciences, with international recognition and positions at leading research institutions. Yet it has not managed to develop a strong ecosystem of biotechnology companies creating new treatments. What has been missing until now?
Your question touches on the starting point of the thinking that led us to create Athens LifeTech Park, the first biotechnology park in Greece and the first of its kind in Southeastern Europe. Our country has excellent scientific talent in the life sciences and biotechnology. Greek scientists excel abroad, holding leadership positions at major international companies in the pharmaceutical and biotechnology sectors. And yet, in Greece, we have not yet built a strong ecosystem that can systematically turn domestic research into programmes for developing new treatments.
The problem, then, is not a lack of talent, but the absence of the right conditions to make use of it. One of the most significant gaps was access to shared, specialist research infrastructure. A scientist who has developed a research idea at a university and wants to turn it into a business venture has nowhere to go. They need laboratory facilities and advanced equipment, as well as an environment that can connect them with investors and experienced entrepreneurs.
Consider a biotechnology startup developing a new treatment that does not yet have any revenue. It is practically impossible for the company to bear, on its own, the cost of building and operating the specialist facilities its research requires. In more developed ecosystems abroad, this gap is filled by specialist biotechnology incubators. They provide access to laboratories, equipment and a broader support network.
In Greece, that kind of access remained limited. At the same time, until a few years ago, the business culture around the commercial use of scientific research was not sufficiently developed. The connection between science and entrepreneurship was often treated as something foreign to academic activity. Fortunately, that mindset is now beginning to change.
“The value of Athens LifeTech Park lies not only in its infrastructure, but in the people, the partnerships and the research programmes we hope to help move forward.”

This culture also seems to be changing at Greek universities, where technology transfer and the commercial use of research are gradually becoming more important. How can this transition be accelerated, and what can an investment of around €80 million, such as Athens LifeTech Park, contribute?
I believe we need to follow a different strategy for developing the domestic ecosystem from the approaches being used abroad. As far as research in Greece is concerned, institutional changes need to be made first and foremost to its funding model, both in the amount of funding available and in how long it lasts. Research in the health sciences takes time, consistency and a long-term commitment. You cannot fund a research programme for two years and expect it to immediately produce a practical solution. Funding needs to be consistent, and our country has not yet secured that to the extent required.
These are, of course, matters of institutional policy, which we cannot change ourselves. Where we can contribute directly is by connecting Greece’s excellent scientific talent with companies and research initiatives from around the world. Our aim is to attract more drug-development activity to Greece, regardless of where the original research comes from. In this way, a critical mass of scientists and professionals with specialised experience in every stage of drug development can gradually take shape.
Creating an appropriate investment environment is equally important. The lack of specialist investment funds was the second major gap we identified. There has been significant progress in this area through EquiFund II, with the participation of the European Investment Fund (EIF), which supported the creation of specialist investment vehicles for the life sciences.
These are investors who understand what makes biotechnology distinctive: the high risk, the long development timelines and the need for patient capital. That is an essential condition for more research ideas to develop into viable businesses.
I understand that your strategy is based to a large extent on “connecting the dots”: linking Greek scientific talent with research teams and companies from abroad, and offering them a place where they can develop their ideas. In healthcare in particular, where specialist facilities and infrastructure are essential, that kind of support cannot be taken for granted.
That’s right. Access to an integrated support environment of this kind remained limited in Greece. That is why we work closely with specialist investment funds, with which we share a strategy that has two strands. The first concerns making use of research produced in Greece. Working with the Technology Transfer Offices at universities and research institutes, we look for research projects with commercial potential that could develop into new biotechnology companies.
The second strand concerns the international scientific and business community, starting with the Greek diaspora and its networks. Many Greek scientists and entrepreneurs work abroad and could develop part of their activity in Greece, drawing on the country’s highly skilled workforce and competitive costs compared with markets such as the United States or Northern Europe.
Our collaboration with investment funds creates mutual benefit in this effort. For these investment vehicles to finance a company, it must have some business activity in Greece. They can therefore provide access to capital, while the companies they finance gain the opportunity to establish research teams and activities here that support their own development plans.
In this way, Greece can attract new biotechnology activity by connecting domestic scientific talent with international business initiatives and investment capital.
Biotechnology is a sector with long development timelines, high costs and significant investment risk. A scientific discovery may take many years to become a treatment. What does a biotech startup really need to move from the lab to the market?
Anyone involved in discovering and developing new medicines knows that failures far outnumber successes. It is one of the most demanding processes, which is why a strong support ecosystem around these efforts is crucial.
Access to funding alone is not enough. You need accumulated experience, specialist expertise and a network of partners who can support the different stages of a treatment’s development. Mature biotechnology ecosystems have established contract research organisations (CROs), which provide specialist research services that a small team cannot carry out on its own.
Developing a medicine requires experiments that may last for years, across different research models and with very different scientific requirements. No small team can have every necessary facility and speciality. The ability to work with reliable, specialist partners is therefore just as important as the scientific idea itself.
“Greece can become an international destination for clinical research. We have scientific talent and infrastructure that the rest of the world does not yet know it can make use of.”
So we are talking about access to specialist teams, infrastructure and expertise. Based on your experience and the investment in Athens LifeTech Park, do you believe Greece can become an international biotechnology hub? And in what area could it gain a real competitive advantage?
This was a question we considered closely while developing the strategy for Athens LifeTech Park. In a way, we had the advantage of starting from scratch, without needing to adapt an already established position for Greece on the international biotechnology map. At the same time, the sector is going through significant change: innovation is rising in China, US policy is changing, and Europe is trying to create conditions that will allow more biotechnology companies to develop within its borders. The question, then, was what Greece could offer that would be genuinely attractive to the international market, and not only to Greek scientists in the diaspora.
I believe the answer lies in clinical research, and clinical trials in particular. Greece has excellent clinical doctors, respected hospitals and an environment in which the trust between doctors and patients can support the development of clinical research. One important step is the operation of a Phase I clinical-trial unit for healthy volunteers at Papageorgiou Hospital in Thessaloniki. We have already signed a memorandum of cooperation with the hospital to strengthen this activity in Greece. For biotechnology companies, one of the most important points at which value is created is the completion of the early clinical stages, particularly Phase II, when meaningful data about a new treatment’s effectiveness begin to emerge.
If we can give biotechnology companies the opportunity to conduct Phase I and Phase II clinical trials in Greece, making use of infrastructure and scientific talent that are not currently being used to their full potential, we will create a real competitive advantage -especially when capacity in other international markets has reached high levels of saturation.
What is interesting is that many of the companies we speak with have not even considered Greece as a possible destination for clinical trials. When we present these opportunities, they are often surprised: “Can we really conduct clinical trials in Greece? Tell us more.” This shows that, alongside developing the necessary infrastructure and partnerships, we also face a major challenge in raising Greece’s international profile: establishing it on the global clinical-research map as a reliable and competitive destination.

Artificial intelligence is now at the centre of almost every discussion about innovation. How much can it accelerate the development of new medicines, and what role do data play in biotechnology?
I’m not an expert in artificial intelligence. However, from what I follow and discuss with our partners, I can see that significant progress has already been made in the early stages of drug development. AI creates new possibilities for designing and optimising drug candidates, allowing researchers to examine more options and tackle complex scientific problems more effectively.
However, the critical point for a new treatment remains testing it in humans: whether it is effective and safe, without causing unpredictable toxic reactions. This is one of the main reasons many potential treatments ultimately fail to progress.
At this stage, we still do not have sufficient data to show that medicines designed with the help of artificial intelligence achieve better clinical outcomes than those developed using traditional methods. It is too early to draw firm conclusions. That does not, of course, diminish AI’s importance in other critical processes.
Optimising the design and conduct of clinical trials, using digital twins and improving research protocols are areas where artificial intelligence can already offer meaningful solutions, helping clinical research to be organised and carried out more effectively.
Athens LifeTech Park is clearly a high-standard investment that aims to change the biotechnology landscape in Greece. How did you experience its official presentation, attended by the prime minister, and what legacy would you like the Park to leave over the next decade?
It was a particularly moving moment for everyone involved in creating Athens LifeTech Park. Building a project like this, with specialist laboratories and shared research infrastructure, is a complex process, both in its design and in its implementation. From the outset, we wanted to create something truly ambitious, even architecturally: a place that would raise the bar and overturn the perception that Greece always lacks the conditions needed to create something that meets international standards. I remember that when the prime minister visited the facilities, he remarked that he felt as if he were in San Francisco. That is exactly the feeling we wanted to create.
Our greatest pride, however, does not come from the building itself, impressive though it may be, but from what we hope will happen inside it. The real value of Athens LifeTech Park will be measured by the people it attracts, the partnerships that develop and the research projects that are able to progress. Our immediate goals include attracting promising biotechnology companies to our incubator, building a dynamic community of scientists and entrepreneurs, and developing our clinical-trial services. At the same time, we want more international companies to begin seeing Greece as a reliable destination for research and development, bringing the corresponding investment capital with them.
Over the next decade, though, our vision is much more specific: for new treatments to be available to the patients who need them, after part of their research and development journey has taken place in Greece, with a meaningful contribution from Greek scientists. That would be the true measure of success for us.

“As the third generation, we are taking over a healthy pharmaceutical company. Our ambition is to use this experience to expand our activity into discovering and developing new treatments.”
To close, I’d like to return to ELPEN, a Greek pharmaceutical company with strong manufacturing and research operations that invests consistently in innovation. What is the next big step your generation hopes to take in the family business?
This is particularly important to us and is connected to the goals each new generation sets, especially in a family business. As the third generation, we are taking over a very healthy company, with strong manufacturing and export operations and an established research and development (R&D) activity.
Our shared ambition is to lead ELPEN into the next stage of its development by taking a meaningful step towards innovation. We are already developing new combinations and improvements to existing pharmaceutical products, applying what we call incremental innovation.
The next challenge is to build on this experience and expand our activity into discovering and developing new treatments. We want to prove that Greek pharmaceutical companies, too, can play a leading role in original pharmaceutical innovation. That is the ambition of our generation and the legacy we want to create for the company’s future.
Translated from Greek. Source: https://www.fortunegreece.com/interview/eleni-pentafragka-to-epomeno-megalo-stoixima-einai-i-elliniki-farmakeftiki-kainotomia/